Formulation and design optimization of repaglinide loaded transferosomes for management of type II diabetes mellitus

Abstract

Background: An anti-diabetic drug called Repaglinide is used to treat type II diabetes. Repaglinide, a lipophilic medication with a short (1 h) half-life and little solubility in water is classified as a class II biopharmaceutical chemical (BCS) chemical. Only around 55% of drugs with a high metabolism in the first pass are bioavailable orally.Objective: The development of repaglinide-loaded transferosomes was the key objective of the current study in order to boost transdermal bioavailability.Method: Thin Film Hydration technique was used to create the transferosomes. Results: SEM examination revealed that the majority of the transfersomes containing repaglinide had spherical forms. Deformable vesicle formulations were found to have an entrapment efficacy of 68.8% to 87.41%. The F9 formulation has high entrapment efficiency (maximum 87.41%). Transfersomes were discovered to improve the release, according to studies on in vitro release. Stability tests for transferosomes were carried out over a three-month period to look at how various levels of temperature affected the total amount of medication entrapped and destroyed, the uniformity of the content, and the physical appearance.Conclusions: Finally, it may be inferred from the available data that transferosomes were a viable option for transdermal distribution, to extend the release and to enhance site specificity of the medication repaglinide.